

Drug patent expirations (2008-2009)

The next few years are expected to be very kind to the generic drug industry and hard to swallow for brand pharmaceutical firms. Below is a list of brand pharmaceuticals that will lose their patents through 2009.

2008

Brand name	Generic name	Manufacturer	Indication/use
Advair	Fluticasone and salmeterol	GlaxoSmithKline	Asthma
Camptosar	Irinotecan	Pfizer	Colon and rectum cancers
Casodex	Bicalutamide	Bristol-Myers Squibb	Prostate cancer
Depakote	Divalproex sodium	Abbott	Epilepsy
Effexor XR	Venlafaxine	Wyeth	Depression
Fosamax	Aledronate	Merck	Osteoporosis
Lamictal	Lamotrigine	GlaxoSmithKline	Epilepsy
Prograf	Tacrolimus	Astellas	Organ rejection
Risperdal	Risperidone	Janssen	Schizophrenia
Serevent	Salmeterol	GlaxoSmithKline	Asthma
Sonata	Zaleplon	King	Insomnia
Topamax	Topiramate	Johnson & Johnson	Migraine
Trusopt	Dorzolamide	Merck	Glaucoma
Zerit	Stavudine	Bristol-Myers Squibb	HIV

2009

Brand name	Generic name	Manufacturer	Indication/use
Acular	Ketorolac tromethamine	Allergan	Eye pain
Arimidex	Anastrozole	AstraZeneca	Breast cancer
Avandia	Rosiglitazone	GlaxoSmithKline	Diabetes
Avelox	Moxifloxacin	Bayer	Antibiotic
Cellcept	Mycophenolate mofetil	Roche	Organ rejection
Flomax	Tamsulosin	Boehringer Ingelheim	BPH
Glyset	Miglitol	Pfizer	Diabetes
Imitrex	Sumatriptan	GlaxoSmithKline	Migraine
Keppra	Levetiracetam	UCB	Epilepsy
Prevacid	Lansoprazole	TAP	Heartburn
Valtrex	Valacyclovir	GlaxoSmithKline	Herpes
Xenical	Orlistat	Roche	Obesity